Why is $NUVB moving today? · SEC 8-K archive

$NUVB SEC Filing Alert & Real-Time AI Stock Impact Analysis

T0 SEO archive for $NUVB: filings appear instantly. AI score, direction and bullet analysis unlock publicly after 4 hours (VIP sees them live).

← All archive signals

FAQ: $NUVB filing catalyst

Why did $NUVB trigger an AI stock catalyst alert?

$NUVB triggered a Stock Catalyst AI alert on 2026-11-04 00:00:00 UTC for a SEC 8-K filing (AI Score: +4.5/10). Headline: Nuvation Bio Reports Q3 2026 Revenue of $45.0M, Net Loss Trims to $(0.12) EPS. Key points: - Total Q3 revenue surged to $45.0M (up from $13.1M YoY), led by $27.5M in IBTROZI net product revenue. - Net loss narrowed to $(41.x)M or $(0.12) per share compared to $(55.8)M or $(0.16) per share in Q3 2025. - Company noted FDA sNDA approval and ROS1 market leadership in new patient starts.

How did $NUVB stock react after the SEC filing?

After the SEC 8-K for $NUVB, observed market reaction: T0 price $4.73. Past moves do not guarantee future results.

Where can I get real-time $NUVB SEC filing alerts?

Stock Catalyst AI pushes real-time SEC 8-K alerts for $NUVB via Telegram and the VIP Web Terminal from €10/month.

$NUVB

$NUVB – Nuvation Bio Reports Q3 2026 Revenue of $45.0M, Net Loss Trims to $(0.12) EPS

Nuvation Bio Inc.

2026-11-04 00:00:00 UTC · SEC 8-K · All $NUVB

Unlocked archive · Analyzed in <2s at T0

Bullish AI Sentiment (+4.5 / 10)

Total Q3 revenue surged to $45.0M (up from $13.1M YoY), led by $27.5M in IBTROZI net product revenue.
Net loss narrowed to $(41.x)M or $(0.12) per share compared to $(55.8)M or $(0.16) per share in Q3 2025.
Company noted FDA sNDA approval and ROS1 market leadership in new patient starts.

Unlock Live VIP Terminal & Telegram – €10/mo Original filing →